Keshav Bhutada becomes CEO of Shilpa Pharma Life Sciences
Shilpa Medicare Limited has announced the appointment of Keshav Bhutada, Executive Director (ED) of Shilpa Pharma Life Sciences Ltd, a material subsidiary of the company, as ED and CEO of Shilpa Pharma Life Sciences.
Keshav is a young and dynamic member of Shilpa’s leadership team, who brings in fresh energy, vision, and a deep commitment to driving innovation and sustainable growth. He is the son of Mr. Vishnukant C Bhutada, Promoter
and Managing Director of Shilpa Medicare Ltd
Keshav Bhutada shared, “I am excited and humbled to take on this responsibility. Shilpa Group has a strong legacy, and I look forward to working with our talented team to build on this foundation, embrace new opportunities, and deliver value to all stakeholders.”
Santosh Mahil will be stepping down as CEO of Shilpa Pharma Life Sciences for personal reasons.
“SPL is a strong organization with some of the best talent in the industry and a leader in APIs, polymers, and peptides. It also stands out as one of the most integrated platforms in the CDMO space. Keshav is a capable and visionary leader who will take the company forward. As I continue my professional journey outside this organization, I extend my best wishes to the entire SPL team and Keshav for continued success,” said Mahil.
As part of the overall re-organisation of group responsibilities, Madhav Bhutada has been assigned the responsibility to oversee the Group’s biologics foray spearheading the Recombinant Albumin & large-scale microbial fermentation facility operations. He also plays a pivotal role in steering growth of biosimilars vertical, contributing to selection of a robust pipeline and actively engaging in fast growing CDMO Biologics business.
